ArticleInfection and drug resistance2022
CD4(+) T Cell Count Progress and Influencing Factors of Recovery in AIDS Patients with Virological Failure in Sichuan Province: A Retrospective Cohort Study.
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Choosing patients with HIV/AIDS (PLWH) with virologic failure observed in the course of treatment, and analyzing the CD4(+) T cell count of PLWH with different subtypes of virus and the risk factors of CD4 (+) T cell count recovery. Methods: Analyze and evaluate the change of median CD4(+) T cell count of PLWH infected with different HIV-1 subtypes in Sichuan Province after treatment by rank sum test. Univariate and multivariate logistic regression models were used to analyze the risk factors on CD4(+) T cell count growth after PLWH treatment. Results: A total of 4977 cases were analysed, including CRF07_BC 2358 cases (47.38%), CRF01_AE 1507 cases (30.28%), CRF08_BC 577 cases (11.59%), CRF85_BC 303 cases (6.09%) and other subtypes 232 cases (4.66%). PLWH infected with CRF85_BC had lower median CD4(+) T cell count after treatment (p < 0.05). It was found that protective factors to increase CD4(+) T cell count (p < 0.05) including females, Yi people, married or cohabiting, educational level at primary school or above, initial and recent treatment with Tenofovir + Lamivudine + Nevirapine Wellen, the second-line regimen with lopinavir/ritonavir (LPV/r) and the treatment time is more than 24 months. However, over 50 years old, the disease course is in AIDS stage, the infection of CRF01_AE and CRF85_BC virus was the risk factor on CD4(+) T cell count increase (p < 0.05). PLWH with higher initial CD4 level had a lower ratio of CD4(+) T cell count increase (≥50 cells/μL) (p < 0.05). Conclusion: Age, sex, ethnicity, marriage, education, disease status, treatment protocols, treatment time, initial CD4(+) T cell count, and virus subtype are the influencing factors of PLWH CD4(+) T cell count increase. The poor recovery of CD4(+) T cell count after treatment was observed in PLWH infected with CRF85_BC virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.